Advertisement

Haloperidol for treatment of cannabinoid hyperemesis syndrome

Published:April 12, 2013DOI:https://doi.org/10.1016/j.ajem.2013.02.021
      Cannabinoid hyperemesis syndrome (CHS) is a condition characterized by cyclical vomiting without other identifiable cause in patients with chronic cannabis use. Patients with CHS report that compulsive bathing and hot showers are the only reliable treatments to improve symptoms. Cannabinoid hyperemesis syndrome is usually unresponsive to conventional pharmacologic antiemetics, and patients often require hospital admission. We report a case of CHS that improved significantly after treatment with haloperidol in the emergency department.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chang Y.H.
        • Windish D.M.
        Cannabinoid hyperemesis relieved by compulsive bathing.
        Mayo Clin Proc. 2009; 84: 76-77
        • Allen J.H.
        • de Moore G.M.
        • Heddle R.
        • et al.
        Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.
        Gut. 2004; 53: 1566-1570
        • Patterson D.A.
        • Smith E.
        • Monahan M.
        • et al.
        Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation.
        J Am Board Fam Med. 2010; 23: 90-93
        • Simonnetto D.A.
        • Oxentenko A.S.
        • Herman M.L.
        • et al.
        Cannabinoid hyperemesis: a case series of 98 patients.
        Mayo Clin Proc. 2012; 87: 114-119
        • Wallace E.A.
        • Andrews S.E.
        • Garmany C.L.
        • Jelley M.J.
        Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm.
        South Med J. 2011; 104: 659-664
        • Gan T.J.
        • Meyer T.
        • Apfel C.C.
        • et al.
        Consensus guidelines for managing postoperative nausea and vomiting.
        Anesth Analg. 2003; 97: 62-71
        • Juurlink D.N.
        Chapter 69. Antipsychotics.
        in: Nelson L.S. Lewin N.A. Howland M.A. Hoffman R.S. Goldfrank L.R. Flomenbaum N.E. Goldfrank's toxicologic emergencies. 9th ed. NY, McGraw-Hill, New York2011: 1003-1015
        • Schulze D.R.
        • Carroll F.I.
        • McMahon L.R.
        Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
        Psychopharmacology. 2012; 222: 425-438
        • Desai R.I.
        • Thakur G.A.
        • Vemuri V.K.
        • et al.
        Analysis of tolerance and behavorial/physical dependance during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists and noncannabinoid drugs.
        J Pharmacol Exp Ther. 2013; 344: 319-328